文献速递产科母胎医学

实时连续血糖监测用于妊娠期糖尿病自我管理的随机对照试验

A randomized controlled trial of real-time continuous glucose monitoring (RT-CGM) for self-management of gestational diabetes.
PubMed 文献 · Am J Obstet Gynecol MFM · 2025-12-17

该开放标签随机对照试验纳入105例妊娠期糖尿病(GDM)患者,比较实时连续血糖监测(RT-CGM)与盲法CGM联合自我血糖监测(SMBG)的效果。母婴结局无显著差异,RT-CGM组满意度高。

要点

  • RT-CGM与SMBG组TIR无显著差异,但RT-CGM组平均血糖更高。
  • RT-CGM组启用胰岛素和/或二甲双胍的比例显著更高。
  • 两组母婴结局无显著差异,RT-CGM组满意度高。

核心结论

  • 在约30周胎龄启动CGM的研究中,RT-CGM组与SMBG组的TIR和平均血糖总体相似,但RT-CGM组更多参与者启用胰岛素。

研究设计与样本

  • 开放标签随机对照试验,纳入105例在14–30周估计胎龄诊断为GDM的患者,随机分配至RT-CGM组(n=53)或盲法CGM组(n=52),均联合SMBG。
  • 分析比较两组在估计胎龄32周和36周(±10天)时的CGM指标。
  • 主要结局为24小时内血糖63–140 mg/dL的目标范围内时间百分比(TIR)。

主要发现

  • 完成研究者的CGM佩戴首日平均估计胎龄为29.8周(SD=2.5),平均佩戴时长64.4天(SD=19.4)。
  • 研究完成时,两组平均血糖和TIR相似。

临床怎么用

  • 在GDM患者约30周胎龄启动RT-CGM未能显著改善TIR,且与更高的平均血糖和更多降糖药物启用相关。
  • RT-CGM组满意度高,但需注意选择偏倚和失访偏倚可能影响结果。
  • 需进一步研究评估更早启动CGM及在高风险人群中使用的潜在获益。

局限性

  • 血糖变化幅度较小,但参与者对CGM兴趣高。
  • 需进一步研究评估更早实施及在高风险人群中使用是否提供获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes mellitus (GDM) - a risk factor for adverse pregnancy outcomes - is on the rise. Real-time continuous glucose monitoring (RT-CGM) may enhance glucose control during GDM and thereby improve outcomes; however, more data are needed. OBJECTIVE: This study aimed to determine if RT-CGM improved glycemic indices in GDM. STUDY DESIGN: An open-label, randomized controlled trial was conducted with GDM patients diagnosed between 14 and 30 weeks estimated gestational age (EGA), assigning them either to RT-CGM or blinded CGM in addition to self-monitoring of blood glucose (SMBG). This analysis compares CGM metrics for the study groups at EGA of 32 and 36 weeks (± 10 days). The primary outcome was percentage of time in range 63 to 140 mg/dL (TIR) over 24 hours. Secondary outcomes included mean glucose over 10 days and additional CGM indices, HbA1c, diabetes medication usage, satisfaction with CGM, and maternal and fetal outcomes. RESULTS: 105 participants with GDM were enrolled (RT-CGM [n=53] or blinded CGM [n=52]) Thirty-one of 52 SMBG participants withdrew, with 30 citing desiring RT-CGM. In participants who completed the study, average EGA was 29.8 weeks (SD=2.5) on their first day of CGM wear with average duration of wear of 64.4 days (SD=19.4). TIR 63-140 mg/dL (TIR) was 93.0 (SD=6.7) and 93.7 (SD=6.8) (p=.86) while mean glucose was 106.7 mg/dL (SD=9.0) and 98.1 mg/dL (SD=13.8) for the RT-CGM and SMBG groups (p=.02), respectively. At study completion, mean glucose and TIR were similar. Insulin and/or metformin use was 66.7% in the RT-CGM group and 33.4% in the SMBG group (p=.02). There were no significant differences in maternal or fetal outcomes. The RT-CGM group's satisfaction with CGM was high. CONCLUSIONS: In this study in which CGM was initiated at about 30 weeks EGA, TIR and mean glucose were similar. However, more participants in the CGM group initiated insulin. Selection and attrition bias could have affected the results. Glycemic changes were minor, but interest in CGM was high. Further research is needed to assess if earlier implementation and use in higher risk populations may provide benefit. El resumen está disponible en Español al final del artículo.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Ehrhardt N, Fonda SJ, Mandava P, et al. A randomized controlled trial of real-time continuous glucose monitoring (RT-CGM) for self-management of gestational diabetes. Am J Obstet Gynecol MFM. 2025. PMID: 41419058. doi:10.1016/j.ajogmf.2025.101878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。